On January 4, 2023 Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, reported that Akari President and CEO Rachelle Jacques will present a company overview at Biotech Showcase 2023 on Monday, January 9, 2023 at 9 am ET (Press release, Akari Therapeutics, JAN 4, 2023, View Source [SID1234625781]). The presentation will include progress highlights from Akari’s two priority pipeline programs: a Phase 3 clinical trial of nomacopan, a novel bispecific inhibitor of complement C5 and leukotriene B4 (LTB4), for the treatment of severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy, and a pre-clinical program investigating long-acting PAS-nomacopan as a potential treatment for geographic atrophy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!